Evaluation of Necrotumic Factor, Fasting Diabetes, Fasting Insulin and Insulin Resistance Levels in Women with Gestational Diabetes

Sarah Jamal Jameel[1*], Sahib J. Abdulrahman[2], Sabah Hussain Khurshid [3]

[1*]*Master student College of Education for Pure Sciences, University of Kirkuk, Kirkuk Iraq.*
[2]*Professor, College of Education for Pure Sciences, University of Kirkuk, Kirkuk, Iraq.*
[3]*Professor, College of Education for Pure Sciences, University of Kirkuk, Kirkuk, Iraq.*

Email: [2]drsahib68@uokirkuk.edu.iq, [3]Sabahkorsheed49@gmail.com
Corresponding Email: [1]jamalsara213@gmail.com*

Abstract: This study aims to examine the concentrations of tumor necrosis factor-α, endothelial growth factors, fasting insulin, fasting blood glucose, and insulin resistance, in 70 women with gestational diabetes in the city of Kirkuk for the period between November 2022 and April 2023 in Kirkuk General Hospital and the medical and specialized clinics. The age of these women ranges between 20-40 years who were divided into two age groups: (20-29) and (30-40). Each group included (35). In addition, the control group included 20 healthy people who did not suffer from any symptoms. After obtaining blood serum, physiological and biochemical tests were conducted. The results show a significant increase ($p{\leq}0.01$) in the concentration of tumor necrosis factor-α (TNF-α), in the level of fasting insulin, fasting blood sugar, and insulin resistance in women with gestational diabetes when compared with the control group. However, both groups of patients (20-29) and (30-40) showed no significant difference in the variables of the study.

1. INTRODUCTION

Gestational diabetes mellitus (GDM) is one of the types of diabetes that was first diagnosed in the second trimester of pregnancy. It is one of the most complicating conditions during pregnancy worldwide, and affects the mother and fetus.1 However, it may disappear after childbirth or may develop into type II sugar. It occurs when beta cells in the pancreas are unable to make enough insulin, especially in the second and third trimesters of pregnancy to maintain healthy blood sugar levels. Furthermore, GDM has become one of the major health problems

that has dramatically increased the world healthcare burden. 2 This causes many problems because diabetes increases the risk of complications during pregnancy. In addition, it increases the risk of developing diabetes in the future newborn. Yet, the pregnant mother recovers from GDM as soon as the child is born, but the first and second types accompany the patient. 3 Tumor Necrosis Factor-α (TNF) plays an important role in Autoimmune diseases, acute and chronic bacterial and viral infections. Women with GDM with gestational diabetes showed an elevated level of tumor necrosis factor-α -α than their uninfected counterparts. 4 These affected women are at the risk of serious complications during pregnancy, including a significant rise in blood pressure and an increased risk of premature birth congenital malformations in the fetus. GDM occurs due to the failure of the pancreas to produce sufficient insulin as a result of dysfunction of beta cells (β-cells) or that the insulin receptors in skeletal muscle cells and fat cells do not respond to insulin. In either case, glucose is unable to enter the cells and accumulates in the blood. Also, the levels of glucose secretion increases in the urine. 5 Insulin resistance refers to the body's inability to use insulin effectively to lower blood sugar levels, as insulin resistance in GDM patients can lead to high blood glucose levels. This increase in the blood glucose may cause complications for both mother and child, as an increase in insulin resistance occurs due to hormones secreted by the placenta, which reduce sensitivity to insulin in the body. 6

2. MATERIALS AND METHODS

Research Designs

This study was conducted in the city of Kirkuk for the period between November 2022 and April 2023. The study included 90 women, 70 GDM pregnant women aged (20-40) years of gestational diabetes after being diagnosed by specialist female doctor and (20) healthy pregnant women who are not (gestational diabetes). All the pregnant women were in the second trimester of pregnancy and the beginning of the last trimester of pregnancy (24-48) weeks from the beginning of pregnancy. They were divided into two groups according to age: (20-29) and (30-40). Then blood samples were collected from patients and healthy people in Kirkuk General Hospital, Azadi Teaching Hospital, Middle East Medical Laboratory, Al-Shafi Laboratory and Al-Methali Specialized Laboratory for pathological analyzes and hormones. All samples underwent laboratory tests examining the concentrations of the tumor necrosis factor-α TNF-α, fasting insulin, fasting sugar, and insulin resistance, in the blood serum. Also, all participants were divided for a comprehensive clinical examination. Then, the patients and the and healthy people were divided into 4 groups based on age:

1-   The first group of (35) patients (20-29)
2-   The second group of (10) normal healthy people (20-29).
3-   The third group of (35) patients (30-40)
4-   The fourth group of (10) normal healthy people (30-40).

Blood Samples

Blood samples were obtained from women with gestational diabetes at a rate of 5 ml. The blood was placed in the Tub Gel test tube and left for 5⁄ minutes at room temperature. Then the

samples were separated by a centrifuge for 15 minutes at 3000 rpm to obtain blood serum. After that, the blood serum was separated and withdrawn in the Eppendorf tubes and kept at (-20) m until the required tests were performed.

Biochemical Analysis
The basic principle to estimating the concentrations of tumor necrosis factor-α, fasting insulin, fasting sugar, and insulin resistance coefficient is the use of the analysis kit from the French company Biolab. It adopts the most updated enzyme-linked immunosorbent assay (ELISA) techniques.

Statistical Analysis
Statistical analyses were conducted using the ready-made statistical program (SPSS) Statistical package for social sciences V 2. The means were extracted and the T-test was used to compare the means of independent samples (independent samples T-test). In addition, the means the paired samples T-test and the difference were considered significant at the level of $p \leq 0.01$), and the immunological and biochemical test values were described as Mean ± standard deviation[7].

3. RESULTS AND DISCUSSIONS

Concentration of Tumor Necrosis Factor-A in the Blood
The results of the current study in Table (1) indicate a significant increase ($p \leq 0.01$) in the concentration of tumor necrosis factor-α in women with GDM, which reached (0.78±0.07) compared to the control group, which amounted to (0.38±0.05) ng/ml. The two patient age groups were compared with the control. The results of this comparison show a significant increase (0.77±0.09) ng/ml in the (20-29 year) age group compared to the control group, which amounted to (0.36±0.04) ng/ml. Also, the age group (30-40) years was (0.79±0.05) ng/ml whereas the control group rose to (0.39±0.06) ng/ml. However, the comparison of the two groups of patients, the results show that the two age groups were similar.

Table 1 Concentration of Alpha Tumor Necrotic Factor TNF-α in Patients' Serum and Control
*Values expressed in SD ±
- Different capital letters mean there is a significant difference ($p \leq 0,01$) between patients and the control and vice versa/
- Different lowercase letters mean that there is a significant difference ($p \leq 0,01$) between the age groups of patients and vice versa.

The results of the current study are consistent with the findings of other studies [8-11], which indicated a high concentration of tumor necrosis factor in women with GDM. This means that there is a positive relationship between GDM and the concentration of alpha tumor necrosis factor. The alpha-tumor necrosis factor TNF-α increased in pregnant women because of its positive and strong association with glycated hemoglobin and insulin resistance as it interferes with the autophosphorylation of insulin receptors insulin receptor substrate (IRS-1). This interference weakens its binding to insulin receptors [12]. This is because GDM is associated

with insulin resistance and poor insulin secretion, and there is an insulin deficiency during pregnancy with high insulin needs to compensate for insulin resistance that develops during the last trimester of pregnancy. In addition, the absorption of glucose in the tissues of the mother tissue depends on insulin and the absorption decreases due to insulin deficiency and hyperglycemia develops after meal. Because the mother-to-placenta glucose transport depends on concentration, maternal hyperglycemia increases glucose transmission from the placenta to the fetus [13].

Fasting Insulin Concentration in Blood Serum
Table (2) shows a significant increase ($p \leq 0.01$) in the means of fasting insulin concentration among women with GDM, which was (11.65 ±1.7) mmol/L when compared with the control group which reached (4.2 ±0.77) mmol/L. The results show a significant increase in the age group (20-29) years, which was (11.22 ±1.5) mmol/l compared to the control group which amounted to (4.28±0.80) mmol/l. Also, the age group (30-40) years was (12.08 ±2.00) mmol/l while the control group achieved (4.17 ±0.78) mmol/L. However, when comparing the two age groups of patients, no significant differences between them appear.

Table 2 Fasting insulin concentration in patients' blood serum and control
Values expressed in SD ±
- Different capital letters mean there is a significant difference ($p \leq 0,01$) between the groups of patients and the control group and vice versa
- Different lowercase letters mean that there is a significant difference ($p \leq 0,01$) between the age groups of patients and vice versa.

The results of our current study are consistent with those of some scholars[14-16]. Beta cells must secrete more insulin to maintain blood sugar against insulin resistance. In the development of type 2 diabetes tests, hyperinsulemia with increased blood sugar precedes the development of hyperglycemia so fasting insulin can be considered as a sign of insulin resistance [15]. Some studies show that fasting insulin rises in women who later develop GDM [16]. The pattern of insulin requirements during pregnancy varies between women with type 1 and type 2 diabetes, indicating a different effect of pregnancy-mediated insulin resistance. Women with type 2 diabetes require a greater increase in insulin dose from the beginning of every trimester and insulin requirements do not decrease at the beginning and end of pregnancy as in women with type 1 diabetes [17].

Fasting Blood Sugar Concentration in Blood Serum
The results of the current study in Table (3) show a significant increase ($p \leq 0.01$) in the means of fasting blood sugar concentration among women with GDM, which amounted to (7.40±1.18) mmol/L when compared with the control group (4.61 ±0.79) mmol/L. When each group of patients is compared with the control group, the results show a significant increase in the age group (20-29) years, which amounted to (7.59 ±1.16) mmol/L, compared to the control group (5.14 ±0.65) mmol/L. The age group (30-40) years was (7.20 ±1.18) mmol/L while the control group was (4.08 ±0.50) mmol/L. However, the comparison of two age groups of patients shows no significant difference between them.

Table (3) Fasting sugar concentration in patients' blood serum and control
Values expressed in SD ±
- Different capital letters mean there is a significant difference (p≤0,01) between the groups of patients and the control groups and vice versa
- Different lowercase letters mean that there is a significant difference (p≤0,01) between the two age groups of patients and vice versa

These results agree with other research works[16, 18] reporting elevated fasting blood sugar concentrations in women with GDM. Pregnant women develop postprandial glycemic responses as growth progresses, unlike fasting glucose levels in which glucose increases after pregnancy by 27-43 mg/100 ml between the first and third trimesters of pregnancy[16].

Insulin Resistance
According to the results of the current study in Table (4-5), the means of insulin resistance) p≤0.01) significantly increased among women with GDM to (3.83±2.04) in relation to the control group, which reached (0.87±0.19). Also, the age group (20-29) significantly rose to (3.78±1.64) compared to the control group, which amounted to (0.98±0.14) while the age group (30-40) years was (3.87±2.31) in comparison to the control group, which was (0.76±0.19). However, the two age groups of patients reveal no significant difference between them.
Table 4 Patient Serum Sulin Resistance Concentration and Control

Values expressed in SD ±
- Different capital letters mean there is a significant difference (p≤0,01) between patients and control and vice versa
- Different lowercase letters mean that there is a significant difference (p≤0,01) between the age groups of patients and vice versa

These results agree with some other studies [19-22]. These studies reported increased insulin resistance in pregnant women. Insulin resistance changes over time during pregnancy, and in the latter half of pregnancy insulin resistance increases significantly and can become severe, especially in women with GDM and type 2 diabetes. Many factors such as placental hormones, obesity, lack of activity, unhealthy diet, and genetic and genetic contributions affect insulin resistance during pregnancy [21]. Insulin resistance is the biological response to a certain internal or external dose of insulin in target tissues (liver, muscle or adipose tissue)[23]. In normal pregnancy, the mother's tissues become increasingly insulin insensitive as a 50-60% reduction in insulin sensitivity has been observed with pregnancy progression in both women with normal glucose tolerance and women with GDM. However, in women with normal glucose tolerance changes in insulin sensitivity are overcome through the increase in insulin production by pancreatic beta cells. Yet, in women with diabetes insulin secretion during pregnancy is insufficient [20]. Increased insulin resistance in skeletal muscles of the mother is an essential feature of GDM patients, which is responsible for increasing the supply of nutrients to the fetus and ultimately enhances fetal obesity. Studies have shown that the pathway of insulin signaling and glucose absorption in skeletal muscles from pregnant women are affected largely due to pro-inflammatory TNF-α cytokines [24, 25].

4. CONCLUSIONS

According to the results, the concentration of tumor necrosis factor-α TNF-α and the concentration of fasting insulin, fasting sugar and insulin resistance increased.

5. REFERENCES

1. X. Zhang and Y. Xiao, "The association between trimester-specific weight gain and severe preeclampsia/adverse perinatal outcome in gestational diabetes mellitus complicated by preeclampsia: a retrospective case study," Diabetes Therapy, vol. 10, pp. 725-734, 2019.
2. A. Lungren, "Program Planning and Evaluation for the Treatment of Women with Gestational Diabetes (GDM) in Rural Northwest Washington," 2023.
3. M. A. Papadakis, S. J. McPhee, and M. C. Rabow, Medical Diagnosis & Treatment. Mc Graw Hill: San Francisco, CA, USA, 2019.
4. L. De Stefano et al., "Tumor necrosis factor-α inhibitor-related immune disorders," Autoimmunity Reviews, p. 103332, 2023.
5. K. A. Nusaif, "Study of correlation between some inflammatory Parameters with insulin resistance in women with gestational diabetes mellitus in Holly Karbala," PhD Unpublished University of Kufa, 2020.
6. M. G. Dalfrà, S. Burlina, G. G. Del Vescovo, and A. Lapolla, "Genetics and epigenetics: new insight on gestational diabetes mellitus," Frontiers in endocrinology, vol. 11, p. 602477, 2020.
7. I. F. Qomusuddin, Statistik pendidikan (Lengkap dengan aplikasi IMB SPSS Statistic 20.0). Deepublish, 2019.
8. R. Melekoglu, O. Ciftci, E. Celik, E. Yilmaz, and A. G. Bastemur, "Evaluation of second trimester amniotic fluid ADAMTS4, ADAMTS5, interleukin-6 and tumor necrosis factor-α levels in patients with gestational diabetes mellitus," Journal of Obstetrics and Gynaecology Research, vol. 45, no. 4, pp. 824-829, 2019.
9. G. Piuri et al., "Methylglyoxal, glycated albumin, PAF, and TNF-α: possible inflammatory and metabolic biomarkers for management of gestational diabetes," Nutrients, vol. 12, no. 2, p. 479, 2020.
10. J. Liu, G. Song, G. Zhao, and T. Meng, "Association between TNF-α polymorphisms and gestational diabetes mellitus: a meta-analysis and trial sequential analysis," Gynecological Endocrinology, vol. 37, no. 6, pp. 506-510, 2021.
11. A. F. Yousif, R. M. Al-Salih, and A. H. Al-Naser, "Evaluation of Maternal serum levels of Adiponectin and Tumor Necrosis Factor-Alpha in Iraqi women with gestational diabetes mellitus," Annals of the Romanian Society for Cell Biology, pp. 3959-3979, 2021.
12. A. Mohammed, I. S. Aliyu, and M. Manu, "Correlation between circulating level of tumor necrosis factor-alpha and insulin resistance in Nigerian women with gestational diabetes mellitus," Annals of African medicine, vol. 17, no. 4, p. 168, 2018.
13. J. Świrska, A. Zwolak, M. Dudzińska, B. Matyjaszek-Matuszek, and T. Paszkowski, "Gestational diabetes mellitus—literature review on selected cytokines and hormones of

confirmed or possible role in its pathogenesis," Ginekologia polska, vol. 89, no. 9, pp. 522-527, 2018.

14. T. Bitó, I. Földesi, T. Nyári, and A. Pál, "Prediction of gestational diabetes mellitus in a high-risk group by insulin measurement in early pregnancy," Diabetic medicine, vol. 22, no. 10, pp. 1434-1439, 2005.

15. E. Grewal et al., "Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects," Metabolism, vol. 61, no. 5, pp. 715-720, 2012.

16. C. E. Powe, "Early pregnancy biochemical predictors of gestational diabetes mellitus," Current diabetes reports, vol. 17, pp. 1-10, 2017.

17. S. Padmanabhan, S. Jiang, M. Mclean, and N. W. Cheung, "Effect of pregnancy on insulin requirements differs between type 1 and type 2 diabetes: a cohort study of 222 pregnancies," Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 56, no. 4, pp. 352-357, 2016.

18. S. Riskin-Mashiah, G. Younes, A. Damti, and R. Auslender, "First-trimester fasting hyperglycemia and adverse pregnancy outcomes," Diabetes care, vol. 32, no. 9, pp. 1639-1643, 2009.

19. K. V. Smirnakis, A. Martinez, K. H. Blatman, M. Wolf, J. L. Ecker, and R. Thadhani, "Early pregnancy insulin resistance and subsequent gestational diabetes mellitus," Diabetes care, vol. 28, no. 5, pp. 1207-1209, 2005.

20. P. Catalano, "Trying to understand gestational diabetes," Diabetic Medicine, vol. 31, no. 3, pp. 273-281, 2014.

21. U. Kampmann, S. Knorr, J. Fuglsang, and P. Ovesen, "Determinants of maternal insulin resistance during pregnancy: an updated overview," Journal of diabetes research, vol. 2019, 2019.

22. G. Ø. Skajaa, J. Fuglsang, U. Kampmann, and P. G. Ovesen, "Parity increases insulin requirements in pregnant women with type 1 diabetes," The Journal of Clinical Endocrinology & Metabolism, vol. 103, no. 6, pp. 2302-2308, 2018.

23. P. M. Catalano, "Obesity, insulin resistance and pregnancy outcome," Reproduction (Cambridge, England), vol. 140, no. 3, p. 365, 2010.

24. H. Alzamil, "Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance," Journal of obesity, vol. 2020, 2020.

25. S. Li et al., "Naringenin improves insulin sensitivity in gestational diabetes mellitus mice through AMPK," Nutrition & diabetes, vol. 9, no. 1, p. 28, 2019.

26. Plata, K., A. Rosato, and G. Węgrzyn, Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochimica Polonica, 2009. 56(4): p. 597-612.PMID: 20011685.

27. Younes, A.A., S.A. Ghara, and S. Samir, Isolation of S. aureus bacteria from dairy products and their identification based on PCR and API 20 techniques. Damascus University Journal of Agricultural Sciences, 2012. 28(1).

28. Otarigho, B. and M.O. Falade, Analysis of antibiotics resistant genes in different strains of Staphylococcus aureus. Bioinformation, 2018. 14(3): p. 113.PMID: 29785070.

29. Akhtar, S., et al., Antibacterial and antiviral potential of colloidal Titanium dioxide (TiO2) nanoparticles suitable for biological applications. Materials Research Express, 2019. 6(10): p. 105409.DOI 10.1088/2053-1591/ab3b27.

30. Tong, S.Y., et al., Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical microbiology reviews, 2015. 28(3): p. 603-661.DOI: 10.1128/CMR.00134-14.

31. Barer, M.R. and W.L. Irving, Medical Microbiology E-Book: A Guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Investigation and Control. 2018: Elsevier Health Sciences.

32. Reddy, P.N., K. Srirama, and V.R. Dirisala, An update on clinical burden, diagnostic tools, and therapeutic options of Staphylococcus aureus. Infectious Diseases: Research and Treatment, 2017. 10: p. 1179916117703999. DOI: 10.1177/1179916117703999.

33. Mathai, J., et al., Haemolysin test for characterization of immune ABO antibodies. Indian Journal of Medical Research, 2003. 118: p. 125-128. PMID: 14700345.

34. Mathur, T., et al., Detection of biofilm formation among the clinical isolates of staphylococci: an evaluation of three different screening methods. Indian journal of medical microbiology, 2006. 24(1): p. 25-29. DOI: 10.4103/0255-0857.19890.

35. MacFaddin, J., Biochemical tests for identification of medical bacteria, williams and wilkins. Philadelphia, PA, 2000. 113(7).

36. Jarlier, V., et al., Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Clinical Infectious Diseases, 1988. 10(4): p. 867-878.DOI: 10.1093/clinids/10.4.867.

37. Dulczak, S. and J. Kirk, Overview of the evaluation, diagnosis, and management of urinary tract infections in infants and children. Urologic nursing, 2005. 25(3).PMID: 16050349.

38. Al-Shawani, A.A.B., Investigation of the gene encoding PVL and some virulence factors in oxacillin-resistant Staphylococcus aureus isolated from different clinical and environmental sources in Kirkuk province. 2022, University of Kirkuk: College of Education for Pure Sciences.

39. Atlas, R.M., A.E. Brown, and L.C. Parks, Laboratory manual of experimental microbiology. 1995: Mosby.

40. Palela, M., et al., Fever temperatures impair hemolysis caused by strains of Escherichia coli and Staphylococcus aureus. Heliyon, 2022. 8(2).DOI: 10.1016 / j.heliyon.2022.e08958.

41. yaseen Hasan, A. and T.K. Ismael, Antimicrobial activity of Loranthus europaeus L. and Lawsonia inermis L. extracts against clinical methicillin-resistant Staphylococcus aureus isolated from boil infections. Tik. J. of Pure Sci., 2018. 23(6): p. 24-30.

42. Al-Sheikhly, M.A.R.H., L.N. Musleh, and H.J. Al-Mathkhury, Gene expression of pelA and pslA in Pseudomonas aeruginosa under gentamicin stress. Iraqi journal of Science, 2020: p. 295-305.DOI: 10.24996 / ijs.2020.61.2.6.

43. Kateete, D.P., et al., Identification of Staphylococcus aureus: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test. Annals of clinical microbiology and antimicrobials, 2010. 9(1): p. 1-7.DOI:10.1186/1476-0711-9-23.

44.   Al-Sadi, L.A.-A.S., The heavy metal tolerance profile and antibiotic sensitivity of Staphylococcus aureus isolated from clinical sources in Baquba city Diyala Journal of Pure Sciences,, 2017. 13(1).DOI: 10.24237 / djps.1301.136A.

45.   Matinfar, S., et al., Phylogenetic and antibiotics resistance in extended-spectrum B-lactamase (ESBL) Uropathogenic Escherichia coli: An update review. Gene Reports, 2021. 23: p. 101-168.DOI:10.1016/j.genrep.2021.101168.

46.   Habibzadeh, A., et al., Prevalence of fungal drug resistance in COVID-19 infection: a global meta-analysis. Current fungal infection reports, 2022. 16(4): p. 154-164. DOI:10.1007/s12281-022-00439-9

47.   Jacobsen, S.M. and M.E. Shirtliff, Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence, 2011. 2(5): p. 460-465.DOI: 10.4161/viru.2.5.17783.

48.   Hernández, H.M., R. Marcet, and J. Sarracent, Biological roles of cysteine proteinases in the pathogenesis of Trichomonas vaginalis. Parasite, 2014. 21.DOI: 10.1051/parasite/2014054.